Showing results (21-30 of 67) with videos related to
Sort By:
Pageof 7
Archivum Immunologiae Et Therapiae Experimentalis|December 10, 2016
Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic LeukemiaLidia Karabon, Anna Partyka, Monika Jasek, et al.Archivum Immunologiae Et Therapiae Experimentalis|December 16, 2015
HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell LymphomaDorota Jesionek-Kupnicka, Marcin Bojo, Monika Prochorec-Sobieszek, et al.Genes, Chromosomes & Cancer|January 27, 2015
Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphomaMarta Bielska, Marcin Bojo, Gabriela Klimkiewicz-Wojciechowska, et al.Genes, Chromosomes & Cancer|December 11, 2012
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemiaEwa Lech-Maranda, Wojciech Mlynarski, Olga Grzybowska-Izydorczyk, et al.European Journal of Haematology|June 9, 2018
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experienceGrzegorz Charlinski, Norbert Grzasko, Artur Jurczyszyn, et al.Clinical and Experimental Medicine|August 31, 2022
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical modelOlga Sokolowska, Anna Rodziewicz-Lurzynska, Zofia Pilch, et al.Archivum Immunologiae Et Therapiae Experimentalis|September 5, 2012
Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation statusEwa Lech-Maranda, Olga Grzybowska-Izydorczyk, Krystyna Wyka, et al.Leukemia & Lymphoma|October 11, 2021
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trialTara Cochrane, Alicia Enrico, David Gomez-Almaguer, et al.Blood|November 21, 2015
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomasMaciej Szydlowski, Przemyslaw Kiliszek, Tomasz Sewastianik, et al.Journal of Cancer Research and Clinical Oncology|February 19, 2022
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphomaMax S Topp, Herbert Eradat, Axel Florschütz, et al.Pageof 7